1Rowe JM. Getting to the root of (it) ALL [J]. Blood, 2010,115 ( 18 ) :3649-3650.
2Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia [ J]. Semin Hematol, 2009,46( 1 ) :64-75.
3Kuhnl A, Gokbuget N, Stroux A, et al. High BAALC expression predicts ehemoresistanee in adult B-precursor acute lymphoblastic leukemia [ J ]. Blood, 2010,115 ( 18 ) :3737-3744.
4Moommn AV, Chilton L, Wilkinson J, et al. A population-based eytogenetic study of adults with acute lymphoblastic leukemia [ J ]. Blood, 2010,115 ( 2 ) :206-214.
5Rowe JM, Buck G, Bumett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993 [ J ]. Blood, 2005,106 ( 12 ) : 3760-3767.
6Ottmann OG, Pfcifer H. Management of Philadelphia chromosomepositive acute lymphoblastie leukemia (Ph + ALL) [ J]. Hematology Am Soc of ttematol Educ Program, 2009,371-381.
7Fielding AK. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia [ J ]. Haematologica, 2010,95 ( 1 ) :8-12.
8Burmeister T, Gokbuget N, Schwartz, 5, et al. Clinical features and prognostic implications of TCF3-PBX1 and TV6-RUNX1 in 'adult acute lymphoblastic leukemia [ J ]. Haematologica, 2010,95(2) :241-246.
9Real PJ, Ferrando AA. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia [ J]. Leukemia, 2009, 23(8) :1374-1377.
8Kim H, Suzuki H, Matsuoka M, et al. Molecular mechanism of the acquisition of new- quinolone resistance in myeobacterium ieprae and mtubereulosis and rapid differentiation methods for resistant bacilli[J]. Nihon Hansenbyo Gakkai Zasshi, 2011,80 (1) :17-27.
9Shinagawa N,Hasegawa M, Hirata K,et al. Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents- special references to bacteria isolated between April 2008 and March 2009[J].Jpn J Antihiot,2010, 63(2):105- 170.
